Comparative Effectiveness of mRNA COVID-19 Vaccines in the Immunocompromised Population: A Systematic Review & Meta-Analysis

The US Centers for Disease Control and Prevention and the Ministry of Health Singapore recommend a third dose of mRNA-1273 or BNT162b2 COVID-19 vaccine as a part of the primary vaccination course in individuals with moderate to severe immunocompromised (IC) conditions. A recent systematic literature review and pairwise meta-analysis comparing the clinical effectiveness of mRNA-1273 versus BNT162b2 in IC individuals found that mRNA-1273 is associated with better clinical outcomes compared with BNT162b2 in the vulnerable IC populations.